Clinical Trial

Leber Congenital Amaurosis Inherited Blindness of Gene Therapy Trial(LIGHT)

Active, Not Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated September 19, 2024 (before its estimated October 30, 2024 completion). Its status may not reflect the trial's current state.
Summary
The purpose of the study is to determine whether HG004 as gene therapy is safe and effective for the treatment of Leber Congenital Amaurosis caused by mutationsin RPE65 gene.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-10-12; most recent amendment 2024-09-08.
Status change: Recruiting → Active, Not Recruiting 2024-09-08
Trial Details
NCT Number NCT06088992
Lead Sponsor Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Collaborators: HuidaGene Therapeutics Co., Ltd.
Conditions Leber Congenital Amaurosis
Enrollment 9 participants
Start Date 2023-01-10
Primary Completion 2024-10-30 (estimated)
Study Completion 2028-10-30 (estimated)
Updated on ClinicalTrials.gov 2024-09-19